SELECTA BIOSCIENCES,INC. (NASDAQ:SELB) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07. Submission of Matters to a Vote of Security Holders.
On June 15, 2018, Selecta Biosciences, Inc. (the “Company”) held its Annual Meeting of Stockholders. A total of 14,113,858 shares of common stock were present in person or represented by proxy at the meeting, representing approximately 63.1 percent of the Company’s outstanding common stock as of the April 20, 2018 record date. The following are the voting results for the proposals considered and voted upon at the meeting, all of which were described in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 25, 2018.
Item 1 – Election of three Class II directors to serve until the 2021 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.
|
NOMINEE |
Votes FOR |
Votes WITHHELD |
Broker Non-Votes |
|
Omid Farokhzad, M.D. |
10,045,080 |
325,329 |
3,743,449 |
|
Amir Nashat, Ph.D. |
10,016,489 |
353,920 |
3,743,449 |
|
Aymeric Sallin |
10,182,457 |
187,952 |
3,743,449 |
Item 2 – Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2018.
|
Votes FOR |
Votes AGAINST |
Votes ABSTAINED |
Broker Non-Votes |
|
14,084,741 |
28,496 |
– |
Based on the foregoing votes, Omid Farokhzad, M.D., Amir Nashat, Ph.D. and Aymeric Sallin were elected as Class II directors and Item 2 was approved.
About SELECTA BIOSCIENCES,INC. (NASDAQ:SELB)
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The Company’s product candidates are in development. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s technology allows for the design of SVP therapies that can stimulate immune responses against a range of relevant antigens. Its initial immune-stimulating product candidate is a synthetic vaccine against nicotine for the market of smoking cessation and relapse prevention.
